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Abstract
Objective: Thyroid proteomics is a new direction in thyroid cancer research aiming at etiological
understanding and biomarker identiﬁcation for improved diagnosis.
Methods: Two-dimensional electrophoresis was applied to cytosolic protein extracts from frozen thyroid
samples (ten follicular adenomas, nine follicular carcinomas, ten papillary carcinomas, and ten
reference thyroids). Spots with differential expression were revealed by image and multivariate
statistical analyses, and identiﬁed by mass spectrometry.
Results: Asetof25proteinspotssigniﬁcantfordiscriminatingbetweenthesamplegroupswasidentiﬁed.
Proteins identiﬁed for nine of these spots were studied further including 14-3-3 protein beta/alpha,
epsilon, and zeta/delta, peroxiredoxin 6, selenium-binding protein 1, protein disulﬁde-isomerase
precursor, annexin A5 (ANXA5), tubulin alpha-1B chain, and a1-antitrypsin precursor. This subset of
protein spots carried the same predictive power in differentiating between follicular carcinoma and
adenoma or between follicular and papillary carcinoma, as compared with the larger set of 25 spots.
Protein expression in the sample groups was demonstrated by western blot analyses. For ANXA5 and
the 14-3-3 proteins, expression in tumor cell cytoplasm was demonstrated by immunohistochemistry
both in the sample groups and an independent series of papillary thyroid carcinomas.
Conclusion: The proteins identiﬁed conﬁrm previous ﬁndings in thyroid proteomics, and suggest
additional proteins as dysregulated in thyroid tumors.
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Introduction
Thyroid cancer constitutes the most prevalent endo-
crine malignancy and comprises a spectrum of indolent
to highly aggressive tumor types derived from the
thyroid follicular or calcitonin-producing cells (1, 2).
Follicular thyroid carcinoma (FTC), papillary thyroid
carcinoma (PTC), and follicular thyroid adenoma (FTA)
originate from the follicular cell, the thyroid gland’s
most abundant structural unit (1). Improved diagnosis
and prognostication of FTA, FTC, and PTC on pre-
operative ﬁne needle aspiration biopsy (FNAB) are
central issues in thyroid cancer research aiming at
optimal treatment schemes for each individual patient.
The FNAB sampling technique has been greatly
facilitated by the use of ultrasonography, but conclusive
distinction between FTA and FTC is not achieved in
about 10–20% of cases (2). Therefore, the identiﬁcation
of molecular markers remains a key issue in thyroid
cytology.
During the past few decades, signiﬁcant progress has
been achieved in deﬁning the molecular etiology of
thyroid cancer. Molecular genetic and cytogenetic
studies have deﬁned common activating events, such
as PPARg rearrangements in FTC, and rearrangements
of RET or NTRK1 as well as BRAF mutations in PTC
(3, 4). Gene expression proﬁling has revealed expression
signatures associated with speciﬁc genetic abnormal-
ities as well as with tumor phenotypes and clinical
course (5, 6, 7, 8). However, it has so far not been
possible to deﬁne a certain set of genes that can be
simply assessed in daily diagnostic routine to unequi-
vocally classify thyroid tumors (2).
More recently, proteomics (i.e. the study of the
proteome) has been gaining ground in thyroid cancer
research. Wilkins et al. (9) were the ﬁrst to deﬁne the
proteome as ‘the complete protein complement expressed
by a genome’. However, since the proteome is highly
dynamic, a more proper deﬁnition should also mention
that this protein complement reﬂects a given cell at a
European Journal of Endocrinology (2012) 166 657–667 ISSN 0804-4643
q 2012 European Society of Endocrinology DOI: 10.1530/EJE-11-0856
Online version via www.eje-online.org
This is an Open Access article distributed under the terms of the European Journal of Endocrinology’s Re-use Licence which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.speciﬁctimepointanditincludesalldifferentisoformsand
modiﬁcations (10). Only a minority of the variation in
protein levels isreﬂected indifferencesatthe mRNA level,
emphasizing the importance of posttranscriptional
regulation of protein abundances (11, 12).
Applying gel-based techniques, e.g. two-dimensional
electrophoresis (2-DE) and mass spectrometric appli-
cations, protein proﬁles can be generated for comparative
analyses of cancer subgroups. At this time, relatively few
proteomic studies on thyroid tumors have been reported
(13, 14, 15, 16, 17, 18). Using proteomics we have
previously identiﬁed a high S100A6 expression
in subcellular protein fractions of PTC as compared with
FTC,FTA,andnormalthyroid(19).Inthepresentstudywe
aimed to combine 2-DE proﬁles on the same studygroups,
with multivariate data analysis for prediction model
building and identiﬁcation of potential tumor markers.
Material and methods
Thyroid tissue samples
Fresh frozen and parafﬁn-embedded samples of tumors
and reference thyroid tissues were obtained from 39
patients operated on for a thyroid tumor at the
Karolinska University Hospital in Stockholm, Sweden.
All samples were collected through the Karolinska
Endocrine Tissue Biobank with informed consent from
patients, and approval granted by the Local Ethics
Committee. Clinical and histopathological details have
been previously reported (19) and are summarized in
Supplementary Table 1, see section on supplementary
data given at the end of this article. In short, tumors
were histopathologically classiﬁed as FTA (nZ10), FTC
(nZ9), or PTC (nZ10). All PTCs were of classic type,
and no case of follicular or anyother variant of PTC was
included. Moreover, both PTCs and FTCs in this study
were well-differentiated tumors. Reference thyroid tissue
samples were nontumor tissue from the contralateral
lobe of ten unrelated patients, who had undergone
thyroidectomy for unilateral tumors. Frozen samples
were used for 2-DE and western blotting, while parafﬁn-
embedded samples from 30 out of these 39 cases
were used for immunohistochemistry. An experienced
histopathologist (A Ho ¨o ¨g) veriﬁed that all samples
were representative for either reference tissue (100%
nontumor thyroid cells) or the corresponding tumor
(O90% tumor cells).
Moreover, formalin-ﬁxed and parafﬁn-embedded
tissue samples from 70 patients with PTC were collected
at the Kyiv City Teaching Endocrinological Centre,
Ukraine. These patients were 18 years of age or younger
at the time of the nuclear accident at the Chornobyl
nuclear power station, lived in nearby areas which
were contaminated, and underwent thyroidectomy
between 2004 and 2008. The Local Ethics Committee
approved the collection and use of these samples.
All tumor cases studied were classiﬁed according to
the latest criteria of the World Health Organization (1),
and have been evaluated for possible presence of
chronic lymphocytic thyroiditis (CLT).
Antibodies
Monoclonal anti-Lamin A/C, clone 636 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and monoclonal
anti-prohibitin, clone II-14-10 (NeoMarkers, Fremont,
CA, USA) were used as nuclear and cytoplasmic markers
of accurate protein fractionations as described (20).T h e
following antibodies were applied for veriﬁcation of
proteins identiﬁed in this study: monoclonal anti-14-3-3
b/3/z (3C8): sc-59420 (Santa Cruz Biotechnology)
against the beta, epsilon, and zeta isoforms of protein
14-3-3; monoclonal anti-PRX VI (1A11): sc-59671
(Santa Cruz Biotechnology) against peroxiredoxin 6
(PRX6); monoclonal anti-annexin V, clone AN5 (Sigma–
Aldrich, Inc.) against annexin A5 (ANXA5); monoclonal
anti-K-ALPHA-1, clone 4D1 (Sigma–Aldrich, Inc.)
against tubulin alpha-1B chain (TUBA1B); monoclonal
anti-A1AT, clone 1C2 (Sigma–Aldrich, Inc.) against
alpha-1 antitrypsin precursor; afﬁnity-isolated anti-
SELENBP1 (Sigma–Aldrich, Inc.) against selenium-
binding protein 1 (SELENBP1); and afﬁnity-isolated
anti-P4HB (ab1; Sigma–Aldrich, Inc.) against protein
disulﬁde-isomerase precursor (PDIp). Monoclonal anti-
b-actin, clone CA-15 (Sigma–Aldrich, Inc.) was used as
control of equal protein loading in immunoblot analyses.
Protein prefractionation
Subcellular protein fractions enriched for cytosolic and
nuclear proteins were extracted from all 39 tissue
samples according to our previously published protocol
(20), quantiﬁed by Bradford assay (21), and veriﬁed by
western blot analyses using anti-Lamin A/C and anti-
prohibitin antibodies as previously reported for the
majority of samples (19, 20).
Two-dimensional electrophoresis
Cytosolic protein extracts from all 39 thyroid tissue
samples were separated by 2-DE, followed by silver
staining using previously established experimental
procedures (22). Brieﬂy, for the ﬁrst dimension (iso-
electric focusing (IEF)) immobilized pH gradient (IPG)
strips with a pH 4–7 range were used (17 cm, Bio-Rad).
Seventy-ﬁve micrograms of protein were diluted in
300 ml rehydration buffer and this solution was applied
on the strips. Active rehydration of the IPG strips and
IEF was performed in a Protean IEF cell (Bio-Rad)
according to the following program: step 1/7, 6 h at
50 V; step 2/7, 6 h at 60 V; step 3/7, 1 h at 60–500 V
(linear); step 4/7, 1 h at 500 V; step 5/7, 2 h at 500–
2000 V (linear); step 6/7, 1 h at 2000–8000 V (linear);
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53 000 V-h on average). Prior to the second dimension,
all strips were incubated in equilibration buffer (50 mM
Tris–HCl (pH 8.8), 69 mM SDS, 6 M urea, and 30%
glycerol) containing 1% dithiothreitol (to achieve
disulﬁde bonds reduction), and subsequently in equili-
bration buffer supplemented with 2.5% iodoacetamide
(to achieve alkylation of SH-groups, thus preventing
protein re- or misfolding). The protein separation was
carried out in an ISO-DALT SDS–PAGE unit (GE
Healthcare, Uppsala, Sweden) using 10–13% linear
gradient acrylamide gels (1.5!200!230 mm, piper-
azine diacrylamide (PDA) as cross-linker) for an average
total of 43 000 V-h.
Following the 2-DE all gels were silver stained
according to a mass spectrometry compatible, modiﬁed
protocol by Rabilloud et al. (23). All gels presenting
high spot resolution, as well as absence of other signs
of problematic protein separation (so called ‘streaking’),
were scanned on a GS-710 ﬂatbed scanner (Bio-Rad,
Hercules,CA,USA)ataresolutionof105.8!105.8 mm.
Spot detection, matching, and intensity measurements
were carried out using PDQuest version 8.0 image
analysis software (Bio-Rad).
2-DE data analysis and spot selection
Principal component analysis (24) and other diagnostic
plots were used to assess the distribution and quality
of data, the presence of outliers as well as the need of
normalization or standardization. Based on the diag-
nostic plots we decided to include all samples and the
data was normalized based on total intensity in valid
spots (each spot’s intensity was divided by the sum of
intensities of all spots on the gel).
Differentially expressed individual proteins were
identiﬁed by univariate statistical analysis. Fold-
changes were calculated for the different subclasses
(FTA, FTC, PTC, and reference thyroid), and compared
using the nonparametric Wilcoxon’s test. P values were
adjusted using the Benjamini and Hochberg false
discovery rate (FDR), taking multiple testing into
account (25). The FDR cut-off value was set to 5%.
Spots present in at least 50% of the samples in one or
more of the tumor subclasses (FTA, FTC, and PTC) were
includedin the multivariate analysis. Partialleast squares
discriminant analysis (PLS-DA) (26, 27) was utilized to
build predictive models and to select gel spots that
contribute to the distinction between the different sample
groups (FTA–FTC and FTC–PTC). To generate the best
predictive PLS model, the number of PLS components
(latent variables) and spots in the model was optimized
andthespotsbestdistinguishingbetweentheclasseswere
identiﬁed. For this purpose, spots were ranked by the PLS-
dependent variable importance on projection (VIP) score
in this study and the most important spots were selected
for prediction (28). The number of spots was decreased by
5% in each step, excluding the lowest-ranked spots, and
the prediction success measures (geometric mean of
sensitivity and speciﬁcity) were evaluated for the number
of PLS components. The PLS modeling was performed
within a bootstrap cross-validation to ascertain a stable
variable selection and model optimization (29). The data
was randomly divided into sets for training (80% of the
samples) and testing (20% of the samples). The different
PLSparameter settings were testedonthe training setand
the resulting success measures when applying the model
to the test set were calculated. This was repeated 500
times and the mean success measures were collected and
plotted. The optimal PLS parameter settings were decided
as the minimal number of PLS components and spots still
giving a good predictive power. The ﬁnal set of spots was
selected based on stability over bootstrap validation
rounds (spots selected in at least 80% of bootstrap rounds
were chosen for further evaluation and identiﬁcation).
Protein digestion, peptide extraction, and mass
spectrometry
Spots were excised manually and prepared for identiﬁ-
cation by mass spectrometry using previously described
experimental procedures (22). Especially for faint spots,
two or more gelplugs corresponding to the same protein
spotwerepooledfromdifferentgels.Theexcisedgelspots
were treated for in-gel digestion as follows: after
removing the silver stain by Farmer’s reagent (50 mM
sodium thiosulphate/15 mM potassium ferricyanide),
andextensivewashingwithwater,gelplugsweretreated
with 50 mM ammonium bicarbonate (ambic) and then
dried by neat acetonitrile (ACN). Porcine trypsin
(modiﬁed, sequence grade from Promega) was added
and incubation continued at 37 8C overnight. Digestion
was terminated by using 10% triﬂuoroacetic acid and
peptide retrieval was facilitated by mechanical vortex
and sonication. The samples were desalted and con-
centrated using a micro-C18 ZipTip (Millipore, Billerica,
MA, USA) and eluted directlyonto the target plate using
alpha-cyano-4-hydroxycinnamic acid in 75% ACN as
matrix. Mass spectra for peptide mass ﬁngerprinting
wereacquiredinpositivereﬂectronmodeonanUltraﬂex
III TOF/TOF (Bruker Daltonics, Bremen, Germany). The
instrument was optimized for the range 600–4500 m/z,
following the manufacturer’s instructions. The spectra
were internally calibrated in quadratic mode using four
autolytic peptides from trypsin (MH
C842.51, 1045.56,
2211.10, and 3337.76 respectively) resulting in an
error of !G0.02 Da. Searches for identities were done
viathe engine ProFound(TheRockefellerUniversityand
National Centre for Research Resources), applying the
latest version of the NCBInr protein sequence database
(NCBInr 2010/02/01) and according to the following
conditions: taxonomy Homo sapiens; mass range
0–300 kDa; pI range 0–14; digestion by trypsin; missed
cuts 1; C2H3ON-Cys as complete and methionine
oxidation as partial modiﬁcation; charge state was
MH
C; and mass tolerance 0.02 Da.
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Protein fractions were resolved by SDS–PAGE in 16%
Tricine gels, blotted onto 0.2 mm nitrocellulose mem-
branes (Invitrogen), and blocked in 3% nonfat milk.
Membranes were subsequently incubated overnight at
4 8Cwiththerespectiveprimaryantibodyatthefollowing
dilutions: anti-Lamin A/C at 1/2000; anti-prohibitin at
1/2000; anti-14-3-3 b/3/z at 1/500; anti-PRX VI
at 1/1000; anti-annexin V at 1/500; anti-K-ALPHA-1
at 1/2000; anti-A1AT at 1/2000; anti-SELENBP1 at
1/2000; anti-P4HB at 1/2000; and anti-b-actin
at 1/16 000. HRP-conjugated goat anti-mouse or
goat anti-rabbit were used as secondary antibodies at
1/12500 dilution. Membranes were exposed to
Amersham Hyperﬁlm ECL ﬁlm (GE Healthcare Limited,
Buckinghamshire, UK).
Immunohistochemistry
Four micrometer parafﬁn sections were deparafﬁnized,
rehydrated, and heated in a microwave oven in citrate
buffer (pH 6) for 20 min. Hydrogen peroxide 0.3% in
water(30 minincubationinroomtemperature(RT))and
avidin (1 h, RT) were used for blocking the endogenous
hyperoxidase activity and biotin respectively. All sections
were then blocked in 1% BSA (20 min, RT) followed by
primary antibody incubation (overnight incubation in a
moist chamber at 4 8C). The monoclonal antibodies
(MAB) anti-14-3-3 b/3/z and anti-annexin V were each
usedatadilutionof1/250.Experimentalconditionswere
optimized after testing various antibody dilutions as well
as incubation solely with either secondary antibody or
avidin–biotin complex (ABC). The ABC method (Vectas-
tain Elite kit; Vector Laboratories, Burlingame, CA, USA)
was applied for 30 min to visualize antibody–antigen
binding, followed by 6 min incubation with diamino-
benzedine tetrahydrochloride and counterstaining with
hematoxylin. Incubation in the absence of a primary
antibody was used as negative control. Immunohisto-
chemical staining was evaluated by four of the authors
(A Ho ¨o ¨g, A Dinets, C Larsson, and A Soﬁadis). Images
were captured usinga ProgRes C12 Plus camera and the
ProgRes Capture Pro 2.5 Software program (Jenoptik,
Jena, Germany). The staining was scored concerning
both the proportion of stained cells (negative, !25,
26–50, and O50%) and the signal intensity (negative,
weak, moderate, and strong).
Results
2-DE proﬁling and spot selection
Cytosolic protein extracts of tissue samples from FTC,
FTA, PTC, and reference thyroid were separated by
2-DE. Using PDQuest an average of 800 protein spots
were detected and matched between the 39 sample gels
included in this study and the virtual master gel, with
a matching rate between individual gel and master gel
of 95–99%. (In PDQuest, master gel is a virtual gel
which depicts each spot’s position and pixel intensity
gathering information from all separate gels within one
experiment.) Univariate analyses revealed at least
twofold increased or decreased intensity for 99 spots
between the FTA and FTC groups (P!0.05, Wilcoxon’s
rank test), and for 27 spots between the FTC and PTC
groups (P!0.05, Wilcoxon’s rank test).
In multivariate analysis by PLS-DA, two predictive
models were built for comparison between FTA and FTC
and between FTC and PTC. Both models displayed a
better predictive power using VIP selected spots
compared with randomly selected ones (Fig. 1). The
FTA–FTC model presented slightly better overall pre-
dictive performance than the FTC–PTC model. The
selection of spots for further validation was based on the
least number of spots still maintaining a good predictive
power as well as stability over bootstrap validation
rounds; spots selected in at least 80% of the 500
bootstrap rounds were considered. This resulted in 25
spots for the FTA–FTC model and 19 spots for the
FTC–PTC model. After visual inspection, one spot from
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Figure 1 Graphical presentation of the performance of the PLS-DA
models built for the comparison between FTA and FTC (A) and
between FTC and PTC (B). The continuous lines correspond to
spots selected after vip-score ranking, whereas dotted lines
correspond to random spot selection. (lat.var., latent variable;
vip, variable importance on projection; and rnd, random).
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shown) was excluded from the investigation, as this was
an elongated, vaguely deﬁned spot very close to the
precipitation line at the acidic edge of the 2-DE gel,
rendering any further analysis unreliable. The 18
resulting spots in the FTC–PTC model all overlapped to
the FTA–FTC model (Table 1). An example of a 2-DE gel
with the 25 spots of interest is shown in Fig. 2.
MALDI-TOF-MS: protein identiﬁcation
Gel plugs for the selected 25 protein spots were
excised, analyzed by MALDI-TOF-MS, and the resulting
spectra were matched against the NCBInr database. The
resulting protein identiﬁcations are summarized in
Table 1, and Fig. 3 compares corresponding individual
spot intensities between samples in the four study
groups. Nine of these proteins were selected for further
analyses – namely 14-3-3 isoforms: b/a, 3, and z/d,
ANXA5, TUBA1B, PRX6, a1-antitrypsin precursor
(A1AT), SELENBP1, and PDIp. The remaining protein
identiﬁcations constituted of heat shock proteins,
calreticulin, protein disulﬁde isomerase A6, ACTB
protein, endoplasmin precursor, creatine kinase
B-type, 78 kDa glucose-regulated protein precursor,
and albumin.
Model of nine selected protein spots: predictive
power
To test the predictive power of the nine selected protein
spots in the FTA–FTC PLS-DA model, a ﬁvefold cross-
validation was applied to all samples (FTA–FTC).
Moreover, we applied a four- and threefold cross-
validation receiving exactly the same result (data not
shown). A PLS-DA model was built on the 25 protein
spots identiﬁed, the nine selected spots as well as nine
randomly picked spots from the list of 25. The resulting
average prediction success over ﬁve cross-validation
rounds showed that the nine selected spots performed as
well as the full set of 25 spots (geometric meanZ1,
positive predictive valueZ1). The nine randomly picked
spots out of the 25 yielded slightly worse prediction
success (geometric meanZ0.94, positive predictive
valueZ0.93). The same control PLS-DA model was
built in the case of the FTC–PTC comparison giving
similar results; 0.90 for the full set of 19 spots, 0.94 for
the seven spots overlapping to the FTA–FTC model and
0.88 for seven spots randomly picked out of the set of
the above-mentioned 19 spots.
Model of nine selected protein spots: validation
of protein expression
The expression of proteins corresponding to the nine
selected spots was qualitatively veriﬁed by western blot
analyses of four samples per group (Fig. 4). For ANXA5,
TUBA1B, PRX6, A1AT, SELENBP1, and PDIp unique
antibodies were applied, while the 14-3-3 isoforms
b/3/z were detected with a single MAB directed against
all three isoforms.
Finally, the expression of two proteins, namely 14-3-3
b/3/z and ANXA5, was further studied by immunohis-
tochemistry (Fig. 5). 14-3-3 was expressed in the
cytoplasm of reference thyroid and tumor cells. In the
latter, positive staining was observed in 33% of FTA
samples, 67% of FTC, and 80% of PTC. For ANXA5
positive staining, mainly located in the cells’ cytoplasm,
was observed in all FTA and PTC samples as well as in
89% of FTC. Given the observation of subsets of
lymphocytes positive for 14-3-3 in PTC, we further
analyzed 70 PTC samples with presence/absence of CLT.
This showed weak to strong 14-3-3 expression in
varying proportions of the cells in 44/68 PTC cases,
with positive and negative CLT areas. ANXA5 showed
weak to strong expression in 50–100% of the tumor
cells in 66/68 PTC cases, all with negative lymphocytes.
Discussion
We here report the identiﬁcation of a set of protein spots
with differential expression in multivariate comparisons
of FTC–FTA and FTC–PTC. Subcellular prefractionated
protein samples from a relatively high number of
samples (nine or ten per group) representing the four
thyroid tissue groups of reference thyroid, FTA, FTC,
and PTC were included in the study. In addition, we
applied multivariate statistical analysis for building a
stable predictive model. The usefulness of prefractiona-
tion in thyroid proteomics e.g. for increased resolution,
has been previously reported for gel-based and other
types of proﬁling (14, 20, 30). In addition, the high
levels of thyroglobulin in thyroid tissues have been
recognized as a possible problem in thyroid proteomic
studies (30). In our study the typical signs of
thyroglobulin described by Krause et al. (30) were not
observed in the 2-DE gels (Fig. 2). A likely explanation
for this difference is that thyroglobulin-containing
vesicles were not fractionated together with cytoplasmic
proteins using the applied protocol for sample fraction-
ation. Hence, thyroglobulin is not expected to have
seriously affected the 2-DE analysis in this study.
Our 2-DE results were analyzed by two different
statistical methods. While the univariate analysis shows
which spots are differently expressed at a certain
signiﬁcance level (5% FDR), the multivariate analysis
is performed to identify the minimum set of spots giving
good predictive performance. For the FTA–FTC compari-
son, 99 spots were identiﬁed by the univariate analysis,
whereas 25 were selected by PLS-DA. The same ﬁgures
for the FTC–PTC comparison were 27 and 19
respectively. This might be related to a varying degree
of common shared characteristics (i.e. protein content)
between FTA–FTC and FTC–PTC respectively. In total,
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www.eje-online.org25 spots were identiﬁed which corresponded to 24
different proteins. Some of these have been previously
described as frequently detected in proteomic studies,
such as hsp b1, 78 kDa glucose-regulated protein (hsp
70 kDa 5), and calreticulin (31). A subset of nine
selected protein spots was shown to yield high predictive
power for the FTC–FTA and FTC–PTC models by
PLS-DA, and expression of the corresponding proteins
was further validated by western blot analyses. Among
these, ANXA5, A1AT, ACTB, SELENBP1, PRX6, and
14-3-3 isoform sigma (s) have been detected in
proteomic proﬁlings of thyroid tissues or by screening
of thyroid tumors (13, 30, 32, 33).
The proteins identiﬁed in this study constitute
candidates that could potentially become thyroid cancer
markers in daily clinical praxis. It is worth mentioning
that, even if some of these proteins seemed to be
individually insigniﬁcant after the univariate statistical
analysis, they were chosen within our PLS-DA multi-
variate model because of their contribution to the
model’s stability and good predictive performance as a
set of proteins. Some of these proteins have also been
implicated in human cancer including thyroid.
Protein 14-3-3 isoforms b/a, 3,a n dz/d were
identiﬁed in this study as signiﬁcant in the FTC–FTA
comparison and 14-3-3 isoforms 3 and z/d were also
signiﬁcant in the FTC–PTC comparison. Furthermore,
14-3-3 expression in tumor cell cytoplasm was
demonstrated by immunohistochemistry. It has recently
been reported that 14-3-3 proteins are involved in fate-
determining cell functions like survival or apoptosis
signaling, tumor suppression, and cell growth, mostly
1809
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Figure 2 Image of a silver-stained 2-DE gel. The 25 spots selected
from the FTA–FTC model are indicated by circles (total overlap with
the 18 spots from the FTC–PTC model). The numbers shown
correspond to the standard spot number automatically assigned to
each spotbythe image analysissoftware (PDQuest). Spotnumbers
followed by an asterisk refer to the nine spots selected for further
validation.
14-3-3 ε
hsp gp96 prec.
hsp gp96 prec. hsp gp96 prec.
hsp gp96 prec. 14-3-3 β/α
Calreticulin prec. 14-3-3 ζ/δ
PDIp
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precursor
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ANXA5
A1AT 78kDa glucose-regulated
protein precursor
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Protein disulfide
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TUBA1B
ACTB protein ACTB protein Creatine kinase
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SELENBP1 ALB protein hsp β1
PRX6
FTA FTC PTC Ref
Thyt
Figure 3 Graphical representation of individual spot intensities for
the 25 spots identiﬁed by PLS-DA across all separate gels included
in the study. Below each graph is given either the full or the
abbreviated name of the corresponding protein identiﬁed by
MALDI-TOF-MS (see Table 1). FTA, follicular thyroid adenoma;
FTC, follicular thyroid carcinoma; Ref thyr, reference thyroid; and
PTC, papillary thyroid carcinoma.
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www.eje-online.orgby integrating various intracellular cues (34). In thyroid
cancer, two studies of the related 14-3-3 isoform s have
shown a nearly exclusive expression of this protein in
PTC (either of conventional type or follicular-variant
PTC), indicating that it plays an important role in the
development of this particular type of tumor (35, 36).
Moreover, Lal et al. (37) have shown that the expression
of 14-3-3(s) in thyroid cancer cells is ruled by the CpG
island hypermethylation. The present study provides
evidencethatthreeothermembersofthe14-3-3 protein
family are expressed in the cytoplasm of thyroid tumor
cells. In 2-DE comparisons, 14-3-3 was found at lower
levels in FTC (Fig. 3), suggesting that 14-3-3 is a
candidate for inclusion in a panel of markers for
differentiation between FTA–FTC or FTC–PTC. However,
further studies are warranted to study the expression
and biologicalrole ofdifferent14-3-3 isoformsincluding
b/a,3,andz/daswellasthesisoforminthyroidtumors.
ANXA5 is a 36 kDa protein which has been mostly
used in combination with radionuclide labeling for the
in vivo detection of apoptosis (38). Evidence for its
possible relation to different cancer forms has been
shown in recent proteomic studies (39, 40, 41). In this
study ANXA5 was detected in both the FTC–FTA and
FTC–PTC comparisons. The expression was veriﬁed by
western blot analysis and also shown to be located in
cytoplasm without staining of lymphocytes, which is
often present especially in PTC.
SELENBP1, a protein which was ﬁrst identiﬁed in
humansin1997byChangetal.(42),hasbeenreportedto
participate in cell functions and processes like aging, lipid
metabolism, protein transportation within the Golgi
apparatus, cell growth, and toxiﬁcation/detoxiﬁcation
processes (43). Decreased levels of SELENBP1 expression
have been reported in lung adenocarcinoma (44, 45),
colorectal adenocarcinoma (46), ovarian cancer (47),
and gastric cancers (48). Recently, Silvers et al. (49)
provided evidence showing that SELENBP1 mRNA
and protein levels decrease as nondysplastic Barrett’s
esophagus progresses to Barrett’s esophagus with
high-grade dysplasia and esophageal adenocarcinoma.
We observed lower levels of protein spots corresponding
to SELENBP1 in PTC in comparison with reference
thyroid tissue (Fig. 3), a ﬁnding that is in concordance
with Brown et al. (13).
PRXs constitute a set of enzymes that serves as part of
a cell’s antioxidant system responsible for maintaining
an appropriate level of reactive oxygen species (ROS).
Zhang et al. (50) recently brought up the issue of the use
of PRXs as targets in cancer radiotherapy, as they
appear to be important not only for the cell’s
detoxiﬁcation from ROS, but also for its proliferation
and survival. PRX6, which is included in our panel of
suggested markers for thyroid tumors, has been
reported to be overexpressed in a variety of tumors
β-Actin
14-3-3
PRX6
PDIp
SELENBP1
ANXA5
A1AT
TUBA1B
PTC FTA FTC Reference thyroid
Figure 4 Western blots illustrating expression of the nine selected
proteins in samples from each study group (reference thyroid, FTA,
FTC, and PTC). b-Actin was used as control of protein loading and
quality in all analyses.
14-3-3 (Ref. thyroid) A
B
ANXA5 (Ref. thyroid)
ANXA5 (FTA)
ANXA5 (FTC)
ANXA5 (PTC)
14-3-3 (FTA)
14-3-3 (FTC)
14-3-3 (PTC)
14-3-3 (PTC/CLT) ANXA5 (PTC/CLT)
Figure 5 Immunohistochemical analysis of protein expression for
14-3-3 (isoforms: b/a, 3 and z/d) and ANXA5. (A) Photomicrographs
in 40! magniﬁcation of parafﬁn sections where predominantly
cytosolic staining is visualized for 14-3-3 and ANXA5 in the different
sample groups. (B) Photomicrographs in 10! magniﬁcation for
14-3-3 and 16! magniﬁcation for ANXA5 analysis on parafﬁn
sections of PTC with CLT visualizing non-stained lymphocytes
together with positively stained tumor cells.
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carcinoma (52), oligodendroglioma, (53) and breast
cancer (41, 54). Thyroid-related studies on PRXs have
so far not concerned PRX6 (55, 56).I nt h i ss t u d yw e
observed low intensities for protein spots corresponding
to PRX6 in FTA in relation to FTC, PTC, and reference
thyroid tissue, and although based on a small number
of cases, western blot analysis (Fig. 4) also suggested
that PRX6 could be underexpressed in FTA. These
observations would suggest a possible role for PRX6 as a
complementarymarkermainly for the distinction ofFTA.
PDIp is the constitutively expressed b subunit of
prolyl 4-hydroxylases (P4Hs), which not only keeps
the hydroxylase’s a subunits in solution, but is also
responsible for maintaining them in a nonaggregated,
catalytically active form (57). Among other functions,
P4Hs are important for cellular responses to hypoxia
(decreased oxygen supply) through the interaction
with hypoxia-induced factors (HIFs) (58, 59). Recently,
Hellman et al. (22) reported the downregulation of PDIp
incervicalcarcinomaincomparisonwithvaginalcancer.
The lower intensities of spots corresponding to PDIp
observedinFTCandPTCascomparedwiththyroidtissue
or FTA (Fig. 3) would be in agreement with a role in the
deregulated HIF mechanism, which renders cancerous
cells able to survive and proliferate in hypoxic conditions.
To summarize, this study has identiﬁed a set of
proteins with differential expression in follicular and
papillary thyroid tumors. A quantitative multimarker
assay, such as multiplexed ELISA or multiple reaction
monitoring (MRM) assay, could be developed and
applied to test the ability of our PLS model to separate
tumor groups. The strength with MRM-based assays is
that the same peptides that lead to the identiﬁcation of
proteins from a gel spot could potentially be selected for
quantitation using targeted proteomics, hence eliminat-
ing difﬁculties with cross-reactivity of antibodies. Upon
veriﬁcation in an independent tumor material, the
clinical utility of proteins like 14-3-3, PRX6, ANXA5,
SELENBP1, or PDIp should be evaluated in prospective
studies, preferably on cytology since the ultimate goal is
to apply this knowledge in FNAB specimens.
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